US6887471B1
(en)
|
1991-06-27 |
2005-05-03 |
Bristol-Myers Squibb Company |
Method to inhibit T cell interactions with soluble B7
|
US7605238B2
(en)
*
|
1999-08-24 |
2009-10-20 |
Medarex, Inc. |
Human CTLA-4 antibodies and their uses
|
US7094874B2
(en)
|
2000-05-26 |
2006-08-22 |
Bristol-Myers Squibb Co. |
Soluble CTLA4 mutant molecules
|
US7455835B2
(en)
|
2000-07-03 |
2008-11-25 |
Bristol-Myers Squibb Company |
Methods for treating immune system diseases using a soluble CTLA4 molecule
|
US20040022787A1
(en)
|
2000-07-03 |
2004-02-05 |
Robert Cohen |
Methods for treating an autoimmune disease using a soluble CTLA4 molecule and a DMARD or NSAID
|
US20020108132A1
(en)
*
|
2001-02-02 |
2002-08-08 |
Avigenics Inc. |
Production of a monoclonal antibody by a transgenic chicken
|
WO2002094202A2
(en)
|
2001-05-23 |
2002-11-28 |
Bristol-Myers Squibb Company |
Methods for protecting allogeneic islet transplant using soluble ctla4 mutant molecules
|
US6578724B1
(en)
*
|
2001-12-29 |
2003-06-17 |
United States Can Company |
Connector for use in packaging aerosol containers
|
NZ536420A
(en)
*
|
2002-04-12 |
2008-04-30 |
Medarex Inc |
Methods of treatment using CTLA-4 antibodies
|
US20040001831A1
(en)
*
|
2002-06-26 |
2004-01-01 |
Millennium Pharmaceuticals, Inc. |
Methods and compositions for the diagnosis and treatment of demyelinating inflammatory disorders
|
CA2517158A1
(en)
*
|
2003-03-03 |
2004-09-16 |
University Of Victoria Innovation And Development Corporation |
Modified aerolysin linked to a lung cancer binding agent and methods of use for treating lung cancer
|
US7465446B2
(en)
*
|
2003-05-30 |
2008-12-16 |
Medarex, Inc. |
Surrogate therapeutic endpoint for anti-CTLA4-based immunotherapy of disease
|
WO2005047324A2
(en)
|
2003-11-10 |
2005-05-26 |
Schering Corp |
Interleukin-10 antibodies
|
WO2005052158A1
(en)
*
|
2003-11-28 |
2005-06-09 |
National Research Council Of Canada |
Anticarcinoma antibidies and uses thereof
|
WO2005115419A1
(en)
*
|
2004-05-17 |
2005-12-08 |
Board Of Trustees Of The University Of Illinois |
USES OF BISPECIFIC ANTIBODY (Biab) COATED DENDRITIC CELLS PULSED WITH ANTIGENS
|
DK2161336T4
(en)
|
2005-05-09 |
2017-04-24 |
Ono Pharmaceutical Co |
Human monoclonal antibodies for programmed death 1 (PD-1) and methods for treating cancer using anti-PD-1 antibodies alone or in combination with other immunotherapies
|
EP1954311A4
(en)
|
2005-12-07 |
2009-12-23 |
Medarex Inc |
Ctla-4 antibody dosage escalation regimens
|
EP2013348A4
(en)
*
|
2006-03-30 |
2009-09-02 |
Univ California |
Methods and compositions for localized secretion of anti-ctla-4 antibodies
|
CN101909693A
(en)
|
2008-01-08 |
2010-12-08 |
百时美施贵宝公司 |
Combination of anti-CTLA4 antibody with tubulin modulating agents for the treatment of proliferative diseases
|
SI2271670T1
(en)
|
2008-03-14 |
2015-01-30 |
Allergan, Inc. |
Immuno-based botulinum toxin serotype a activity assays
|
EP2286220A2
(en)
*
|
2008-05-29 |
2011-02-23 |
Bristol-Myers Squibb Company |
Methods for predicting patient response to modulation of the co-stimulatory pathway
|
WO2010014784A2
(en)
|
2008-08-01 |
2010-02-04 |
Bristol-Myers Squibb Company |
Combination of anti-ctla4 antibody with diverse therapeutic regimens for the synergistic treatment of proliferative diseases
|
EA201790824A3
(en)
|
2008-09-26 |
2017-12-29 |
Токаджен Инк. |
VECTORS FOR GENETIC THERAPY AND CYTOZINDESAMINASE
|
US8475790B2
(en)
|
2008-10-06 |
2013-07-02 |
Bristol-Myers Squibb Company |
Combination of CD137 antibody and CTLA-4 antibody for the treatment of proliferative diseases
|
CA2737045C
(en)
*
|
2008-11-20 |
2017-11-14 |
Bruce Kabakoff |
Therapeutic protein formulations
|
EP3281953B1
(en)
|
2009-03-13 |
2019-10-02 |
Allergan, Inc. |
Immuno-based retargeted endopeptidase activity assays
|
EP2456790A1
(en)
|
2009-07-20 |
2012-05-30 |
Bristol-Myers Squibb Company |
Combination of anti-ctla4 antibody with diverse therapeutic regimens for the synergistic treatment of proliferative diseases
|
WO2011036467A1
(en)
*
|
2009-09-24 |
2011-03-31 |
Russell David Keenan |
Products useful in the treatment of haemophilia
|
EP2545073B1
(en)
|
2010-03-12 |
2015-09-30 |
AbbVie Biotherapeutics Inc. |
Ctla4 proteins and their uses
|
RU2612788C2
(en)
|
2010-03-23 |
2017-03-13 |
Интрексон Корпорейшн |
Vectors conditionally expressing therapeutic proteins, host cells comprising the vectors, and uses thereof
|
EP2571577A1
(en)
|
2010-05-17 |
2013-03-27 |
Bristol-Myers Squibb Company |
Improved immunotherapeutic dosing regimens and combinations thereof
|
EP2643694B1
(en)
|
2010-11-24 |
2018-01-03 |
Litron Laboratories Ltd. |
Rapid in vivo gene mutation assay based on the pig-a gene
|
WO2012097313A2
(en)
|
2011-01-14 |
2012-07-19 |
The Regents Of The University Of California |
Therapeutic antibodies against ror-1 protein and methods for use of same
|
GB201103955D0
(en)
*
|
2011-03-09 |
2011-04-20 |
Antitope Ltd |
Antibodies
|
CA2834548C
(en)
|
2011-04-28 |
2021-06-01 |
The Broad Institute, Inc. |
Inhibitors of histone deacetylase
|
US20150110779A1
(en)
|
2012-03-15 |
2015-04-23 |
Bristol-Myers Squibb Company |
Methods for predicting gastrointestinal immune-related adverse events (gi-irae) in patients treated with modulation of the co-stimulatory pathway
|
US20150079100A1
(en)
|
2012-03-23 |
2015-03-19 |
Bristol-Myers Squibb Company |
Methods of treatments using ctla-4 antibodies
|
US20150118244A1
(en)
|
2012-05-10 |
2015-04-30 |
Bristol-Myers Squibb Company |
Anti-tumor antibodies as predictive or prognostic biomarkers of efficacy and survival in ipilimumab-treated patients
|
US9856320B2
(en)
|
2012-05-15 |
2018-01-02 |
Bristol-Myers Squibb Company |
Cancer immunotherapy by disrupting PD-1/PD-L1 signaling
|
EP2877444B1
(en)
|
2012-07-27 |
2020-09-02 |
The Broad Institute, Inc. |
Inhibitors of histone deacetylase
|
US10034939B2
(en)
|
2012-10-26 |
2018-07-31 |
The University Of Chicago |
Synergistic combination of immunologic inhibitors for the treatment of cancer
|
WO2015042707A1
(en)
|
2013-09-24 |
2015-04-02 |
Medicenna Therapeutics Pte Ltd |
Interleukin-2 fusion proteins and uses thereof
|
EP3065772A4
(en)
|
2013-11-05 |
2017-09-13 |
Cognate Bioservices, Inc. |
Combinations of checkpoint inhibitors and therapeutics to treat cancer
|
EP3066127A1
(en)
|
2013-11-06 |
2016-09-14 |
Bristol-Myers Squibb Company |
Immunotherapeutic dosing regimens and combinations thereof
|
WO2015082724A1
(en)
|
2013-12-08 |
2015-06-11 |
Peptcell Limited |
Hiv antigens and antibodies and compositions, methods and uses thereof
|
EP3114144A1
(en)
|
2014-03-05 |
2017-01-11 |
Bristol-Myers Squibb Company |
Treatment of renal cancer using a combination of an anti-pd-1 antibody and another anti-cancer agent
|
JP6592505B2
(en)
|
2014-04-24 |
2019-10-16 |
ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー |
Interleukin-2 super antagonist, partial agonist and antagonist
|
MX2016014753A
(en)
|
2014-05-15 |
2017-03-06 |
Bristol Myers Squibb Co |
Treatment of lung cancer using a combination of an anti-pd-1 antibody and another anti-cancer agent.
|
SG11201609721WA
(en)
|
2014-05-28 |
2016-12-29 |
Agenus Inc |
Anti-gitr antibodies and methods of use thereof
|
CN105296433B
(en)
|
2014-08-01 |
2018-02-09 |
中山康方生物医药有限公司 |
A kind of CTLA4 antibody, its medical composition and its use
|
EP3180018B1
(en)
|
2014-08-12 |
2019-07-24 |
Massachusetts Institute Of Technology |
Synergistic tumor treatment with il-2 and integrin-binding-fc-fusion protein
|
US20170216403A1
(en)
|
2014-08-12 |
2017-08-03 |
Massachusetts Institute Of Technology |
Synergistic tumor treatment with il-2, a therapeutic antibody, and an immune checkpoint blocker
|
ES2908056T3
(en)
|
2014-10-10 |
2022-04-27 |
Idera Pharmaceuticals Inc |
Cancer treatment by TLR9 agonists with checkpoint inhibitors
|
JP2017537927A
(en)
|
2014-12-04 |
2017-12-21 |
ブリストル−マイヤーズ スクイブ カンパニーBristol−Myers Squibb Company |
Combination of anti-CS1 and anti-PD1 antibodies to treat cancer (myeloma)
|
EP3256165B1
(en)
*
|
2015-02-13 |
2021-07-14 |
Sorrento Therapeutics, Inc. |
Antibody therapeutics that bind ctla4
|
US20180133327A1
(en)
|
2015-03-16 |
2018-05-17 |
Amal Therapeutics Sa |
Cell Penetrating Peptides and Complexes Comprising the Same
|
US10376535B2
(en)
|
2015-03-26 |
2019-08-13 |
University Of Rochester |
Therapy for malignant disease
|
WO2016164799A1
(en)
|
2015-04-10 |
2016-10-13 |
The Regents Of The University Of California |
Methods of determining patient populations amenable to immunomodulatory treatment of cancer
|
MY188749A
(en)
|
2015-04-17 |
2021-12-28 |
Bristol Myers Squibb Co |
Compositions comprising a combination of nivolumab and ipilimumab
|
KR20170138555A
(en)
|
2015-04-28 |
2017-12-15 |
브리스톨-마이어스 스큅 컴퍼니 |
Treatment of PD-L1-negative melanoma with anti-PD-1 antibody and anti-CTLA-4 antibody
|
KR20170140316A
(en)
|
2015-04-28 |
2017-12-20 |
브리스톨-마이어스 스큅 컴퍼니 |
Treatment of PD-L1-positive melanoma with anti-PD-1 antibody
|
JP7028765B2
(en)
|
2015-05-22 |
2022-03-02 |
トランスレイショナル・ドラッグ・ディベロップメント・エルエルシー |
Benzamide and active compound compositions and methods of use
|
WO2016191751A1
(en)
|
2015-05-28 |
2016-12-01 |
Bristol-Myers Squibb Company |
Treatment of pd-l1 positive lung cancer using an anti-pd-1 antibody
|
WO2016196389A1
(en)
|
2015-05-29 |
2016-12-08 |
Bristol-Myers Squibb Company |
Treatment of renal cell carcinoma
|
CN107849144B
(en)
|
2015-05-29 |
2021-09-17 |
艾吉纳斯公司 |
anti-CTLA-4 antibodies and methods of use thereof
|
PT3313528T
(en)
|
2015-06-29 |
2021-09-16 |
Bristol Myers Squibb Co |
Immunotherapeutic dosing regimens comprising pomalidomide and an anti-cs1 antibody for treating cancer
|
WO2017011666A1
(en)
|
2015-07-14 |
2017-01-19 |
Bristol-Myers Squibb Company |
Method of treating cancer using immune checkpoint inhibitor
|
US10786547B2
(en)
|
2015-07-16 |
2020-09-29 |
Biokine Therapeutics Ltd. |
Compositions, articles of manufacture and methods for treating cancer
|
EP3322448A4
(en)
|
2015-07-16 |
2019-03-06 |
Bioxcel Therapeutics, Inc. |
A novel approach for treatment of cancer using immunomodulation
|
US10660954B2
(en)
|
2015-07-31 |
2020-05-26 |
University Of Florida Research Foundation, Incorporated |
Hematopoietic stem cells in combinatorial therapy with immune checkpoint inhibitors against cancer
|
US20180222990A1
(en)
|
2015-08-04 |
2018-08-09 |
Glaxosmithkline Intellectual Property Development Limited |
Combination Treatments and Uses and Methods Thereof
|
WO2017025871A1
(en)
|
2015-08-07 |
2017-02-16 |
Glaxosmithkline Intellectual Property Development Limited |
Combination therapy comprising anti ctla-4 antibodies
|
CA2996059A1
(en)
*
|
2015-08-28 |
2017-03-09 |
Alector Llc |
Anti-siglec-7 antibodies and methods of use thereof
|
US10323091B2
(en)
|
2015-09-01 |
2019-06-18 |
Agenus Inc. |
Anti-PD-1 antibodies and methods of use thereof
|
KR20180071386A
(en)
|
2015-11-18 |
2018-06-27 |
브리스톨-마이어스 스큅 컴퍼니 |
Treatment of lung cancer using a combination of anti-PD-1 antibody and anti-CTLA-4 antibody
|
KR20180083944A
(en)
|
2015-12-02 |
2018-07-23 |
아게누스 인코포레이티드 |
Antibodies and methods for their use
|
AR107781A1
(en)
|
2015-12-14 |
2018-06-06 |
Macrogenics Inc |
BISPECIFIC MOLECULES THAT HAVE IMMUNORREACTIVITY WITH PD-1 AND CTLA-4, AND METHODS OF USE OF THE SAME
|
WO2017120612A1
(en)
|
2016-01-10 |
2017-07-13 |
Modernatx, Inc. |
Therapeutic mrnas encoding anti ctla-4 antibodies
|
WO2017160599A1
(en)
|
2016-03-14 |
2017-09-21 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Use of cd300b antagonists to treat sepsis and septic shock
|
AU2017234163B2
(en)
|
2016-03-15 |
2023-01-19 |
Mersana Therapeutics, Inc. |
NaPi2b-targeted antibody-drug conjugates and methods of use thereof
|
EP3429618B1
(en)
|
2016-03-16 |
2024-02-21 |
Amal Therapeutics SA |
Combination of an immune checkpoint modulator and a complex comprising a cell penetrating peptide, a cargo and a tlr peptide agonist for use in medicine
|
TW201735949A
(en)
|
2016-03-24 |
2017-10-16 |
千禧製藥公司 |
Methods of treating gastrointestinal immune-related adverse events in anti-CTLA4 anti-PD-1 combination treatments
|
WO2017165778A1
(en)
|
2016-03-24 |
2017-09-28 |
Millennium Pharmaceuticals, Inc. |
Methods of treating gastrointestinal immune-related adverse events in immune oncology treatments
|
US11209441B2
(en)
|
2016-04-05 |
2021-12-28 |
Bristol-Myers Squibb Company |
Cytokine profiling analysis
|
WO2017192874A1
(en)
|
2016-05-04 |
2017-11-09 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Albumin-binding immunomodulatory compositions and methods of use thereof
|
CA3024509A1
(en)
|
2016-05-18 |
2017-11-23 |
Modernatx, Inc. |
Mrna combination therapy for the treatment of cancer
|
MX2018013868A
(en)
|
2016-05-20 |
2019-02-21 |
Biohaven Pharm Holding Co Ltd |
Use of glutamate modulating agents with immunotherapies to treat cancer.
|
US11623958B2
(en)
|
2016-05-20 |
2023-04-11 |
Harpoon Therapeutics, Inc. |
Single chain variable fragment CD3 binding proteins
|
US11090344B2
(en)
|
2016-05-27 |
2021-08-17 |
Dnatrix, Inc. |
Adenovirus and immunomodulator combination therapy
|
CN109641044A
(en)
|
2016-05-30 |
2019-04-16 |
吉奥瓦科斯公司 |
For generating composition and method to the immune response of hepatitis type B virus
|
ES2954139T3
(en)
|
2016-06-02 |
2023-11-20 |
Bristol Myers Squibb Co |
PD-1 Blockade With Nivolumab in Refractory Hodgkin Lymphoma
|
CN109476754A
(en)
|
2016-06-03 |
2019-03-15 |
百时美施贵宝公司 |
Purposes of the anti-PD-1 antibody in treatment colorectal cancer patients
|
KR20190015407A
(en)
|
2016-06-03 |
2019-02-13 |
브리스톨-마이어스 스큅 컴퍼니 |
Anti-PD-1 antibody for use in the treatment of recurrent small cell lung cancer
|
SG11201810509PA
(en)
|
2016-06-20 |
2018-12-28 |
Kymab Ltd |
Anti-pd-l1 antibodies
|
CA3029426A1
(en)
|
2016-06-30 |
2018-01-04 |
Oncorus, Inc. |
Pseudotyped oncolytic viral delivery of therapeutic polypeptides
|
AU2017297603A1
(en)
|
2016-07-14 |
2019-02-14 |
Fred Hutchinson Cancer Research Center |
Multiple bi-specific binding domain constructs with different epitope binding to treat cancer
|
NL2017270B1
(en)
*
|
2016-08-02 |
2018-02-09 |
Aduro Biotech Holdings Europe B V |
New anti-hCTLA-4 antibodies
|
US11649289B2
(en)
|
2016-08-04 |
2023-05-16 |
Glaxosmithkline Intellectual Property Development Limited |
Anti-ICOS and anti-PD-1 antibody combination therapy
|
WO2018035710A1
(en)
|
2016-08-23 |
2018-03-01 |
Akeso Biopharma, Inc. |
Anti-ctla4 antibodies
|
KR20190057345A
(en)
|
2016-09-21 |
2019-05-28 |
아말 테라퓨틱스 에스에이 |
Fusions comprising cancer cell-mediated peptides, multi-epitopes and TLR peptide agonists for cancer therapy
|
MA46529A
(en)
|
2016-10-11 |
2019-08-21 |
Agenus Inc |
ANTI-LAG-3 ANTIBODIES AND PROCESSES FOR USE
|
CN110099925A
(en)
|
2016-10-28 |
2019-08-06 |
百时美施贵宝公司 |
Use the method for anti-PD-1 Antybody therapy urothelial cancer
|
US11135307B2
(en)
|
2016-11-23 |
2021-10-05 |
Mersana Therapeutics, Inc. |
Peptide-containing linkers for antibody-drug conjugates
|
US10780080B2
(en)
|
2016-11-23 |
2020-09-22 |
Translational Drug Development, Llc |
Benzamide and active compound compositions and methods of use
|
BR112019010878A2
(en)
|
2016-11-29 |
2019-10-01 |
Lindhofer Horst |
combination of multifunctional t-cell redirection antibodies with immune checkpoint modulators and their uses
|
CN110234342A
(en)
|
2016-12-01 |
2019-09-13 |
葛兰素史密斯克莱知识产权发展有限公司 |
Combination treatment
|
BR112019011370A2
(en)
|
2016-12-01 |
2019-10-15 |
Glaxosmithkline Ip Dev Ltd |
combination therapy
|
IL266918B2
(en)
|
2016-12-07 |
2024-03-01 |
Agenus Inc |
Anti-ctla-4 antibodies and methods of use thereof
|
EP3552126A1
(en)
|
2016-12-09 |
2019-10-16 |
Regeneron Pharmaceuticals, Inc. |
Systems and methods for sequencing t cell receptors and uses thereof
|
US20200095301A1
(en)
|
2016-12-14 |
2020-03-26 |
The Board Of Trustees Of The Leland Stanford Junior University |
Il-13 superkine: immune cell targeting constructs and methods of use thereof
|
US10350266B2
(en)
|
2017-01-10 |
2019-07-16 |
Nodus Therapeutics, Inc. |
Method of treating cancer with a multiple integrin binding Fc fusion protein
|
AU2018207303A1
(en)
|
2017-01-10 |
2019-07-25 |
xCella Biosciences, Inc. |
Combination tumor treatment with an integrin-binding-Fc fusion protein and immune modulator
|
US20180271996A1
(en)
|
2017-02-28 |
2018-09-27 |
Mersana Therapeutics, Inc. |
Combination therapies of her2-targeted antibody-drug conjugates
|
JP2020513819A
(en)
*
|
2017-03-15 |
2020-05-21 |
スージョウ ギャラクシー バイオファーマ カンパニー リミテッド |
CTLA4 antibody, pharmaceutical composition and use thereof
|
WO2018183928A1
(en)
|
2017-03-31 |
2018-10-04 |
Bristol-Myers Squibb Company |
Methods of treating tumor
|
TWI788340B
(en)
|
2017-04-07 |
2023-01-01 |
美商必治妥美雅史谷比公司 |
Anti-icos agonist antibodies and uses thereof
|
CA3060516A1
(en)
|
2017-04-21 |
2018-10-25 |
Sillajen, Inc. |
Oncolytic vaccinia virus and checkpoint inhibitor combination therapy
|
SG10202107880XA
(en)
|
2017-05-12 |
2021-09-29 |
Harpoon Therapeutics Inc |
Mesothelin binding proteins
|
AU2018277559A1
(en)
|
2017-05-30 |
2019-10-17 |
Bristol-Myers Squibb Company |
Compositions comprising a combination of an anti-LAG-3 antibody, a PD-1 pathway inhibitor, and an immunotherapeutic agent
|
BR112019024291A2
(en)
|
2017-06-09 |
2020-07-28 |
Providence Health & Services-Oregon |
use of cd39 and cd103 for the identification of reactive human tumor t cells for the treatment of cancer
|
CN111201035A
(en)
|
2017-06-19 |
2020-05-26 |
梅迪塞纳医疗股份有限公司 |
Uses and methods for IL-2 superagonists, agonists, and fusions thereof
|
JP2020536051A
(en)
|
2017-09-20 |
2020-12-10 |
リジェネロン・ファーマシューティカルズ・インコーポレイテッドRegeneron Pharmaceuticals, Inc. |
Immunotherapeutic agents for patients whose tumors carry high passenger gene mutations
|
KR20200064132A
(en)
|
2017-10-15 |
2020-06-05 |
브리스톨-마이어스 스큅 컴퍼니 |
How to treat a tumor
|
US11638760B2
(en)
|
2017-11-27 |
2023-05-02 |
Mersana Therapeutics, Inc. |
Pyrrolobenzodiazepine antibody conjugates
|
EP4295915A2
(en)
*
|
2017-12-20 |
2023-12-27 |
Harbour Biomed (Shanghai) Co., Ltd |
Antibodies binding ctla-4 and uses thereof
|
JP2021506883A
(en)
|
2017-12-21 |
2021-02-22 |
メルサナ セラピューティクス インコーポレイテッド |
Pyrrolobenzodiazepine antibody conjugate
|
JP2021508477A
(en)
|
2017-12-29 |
2021-03-11 |
オンコラス, インコーポレイテッド |
Oncolytic virus delivery of therapeutic polypeptides
|
JP2021510733A
(en)
|
2018-01-12 |
2021-04-30 |
ケーディーエーシー セラピューティクス,インコーポレーテッドKdac Therapeutics, Inc. |
Combination of selective histone deacetylase 3 (HDAC3) inhibitor and immunotherapeutic agent for the treatment of cancer
|
US20210363242A1
(en)
|
2018-01-16 |
2021-11-25 |
Bristol-Myers Squibb Company |
Methods of treating cancer with antibodies against tim3
|
JP2021517589A
(en)
|
2018-03-12 |
2021-07-26 |
アンセルム(アンスティチュート・ナシオナル・ドゥ・ラ・サンテ・エ・ドゥ・ラ・ルシェルシュ・メディカル) |
Use of calorie restriction mimics to enhance chemoimmunotherapy for the treatment of cancer
|
CA3093407A1
(en)
|
2018-03-23 |
2019-09-26 |
Bristol-Myers Squibb Company |
Antibodies against mica and/or micb and uses thereof
|
WO2019191676A1
(en)
|
2018-03-30 |
2019-10-03 |
Bristol-Myers Squibb Company |
Methods of treating tumor
|
TW202017569A
(en)
|
2018-05-31 |
2020-05-16 |
美商佩樂敦治療公司 |
Compositions and methods for inhibiting cd73
|
GB201809050D0
(en)
|
2018-06-01 |
2018-07-18 |
E Therapeutics Plc |
Modulators of tryptophan catabolism
|
KR20210035805A
(en)
|
2018-06-15 |
2021-04-01 |
플래그쉽 파이어니어링 이노베이션스 브이, 인크. |
Increased immune activity through regulation of postcellular signaling factors
|
AU2019285344A1
(en)
|
2018-06-15 |
2020-12-10 |
Mina Therapeutics Limited |
Combination therapies comprising C/EBP alpha saRNA
|
US20210277135A1
(en)
|
2018-07-13 |
2021-09-09 |
Bristol-Myers Squibb Company |
Ox-40 agonist, pd-1 pathway inhibitor and ctla-4 inhibitor combination for use in a method of treating a cancer or a solid tumor
|
JP2021534101A
(en)
|
2018-08-09 |
2021-12-09 |
ヴェルソー セラピューティクス, インコーポレイテッド |
Oligonucleotide compositions for targeting CCR2 and CSF1R and their use
|
WO2020048942A1
(en)
|
2018-09-04 |
2020-03-12 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and pharmaceutical compositions for enhancing cytotoxic t lymphocyte-dependent immune responses
|
JP2022511337A
(en)
|
2018-09-19 |
2022-01-31 |
インサーム (インスティテュート ナショナル デ ラ サンテ エ デ ラ ルシェルシェ メディカル) |
Methods and Pharmaceutical Compositions for the Treatment of Cancers Resistant to Immune Checkpoint Treatment
|
MX2021003554A
(en)
|
2018-09-25 |
2021-05-27 |
Harpoon Therapeutics Inc |
Dll3 binding proteins and methods of use.
|
BR112021004383A2
(en)
|
2018-09-28 |
2021-08-03 |
Massachusetts Institute Of Technology |
immunomodulatory fusion protein, pharmaceutical composition, nucleic acid, expression vector, transformed cell, method for producing an immunomodulatory fusion protein, method for activating, enhancing or promoting a response by an immune cell in a subject, method for inhibiting, reducing or suppressing a response by an immune cell in a subject, method of reducing or inhibiting tumor growth, method of treating cancer in a subject, kit, use of an immunomodulatory fusion protein, and method of reducing or inhibiting tumor growth or treat cancer in a subject
|
US20220040183A1
(en)
|
2018-10-01 |
2022-02-10 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Use of inhibitors of stress granule formation for targeting the regulation of immune responses
|
KR20210081384A
(en)
|
2018-10-23 |
2021-07-01 |
브리스톨-마이어스 스큅 컴퍼니 |
how to treat a tumor
|
KR20210084546A
(en)
|
2018-10-29 |
2021-07-07 |
메르사나 테라퓨틱스, 인코포레이티드 |
Cysteine Engineered Antibody-Drug Conjugates with Peptide-Containing Linkers
|
WO2020102501A1
(en)
|
2018-11-16 |
2020-05-22 |
Bristol-Myers Squibb Company |
Anti-nkg2a antibodies and uses thereof
|
AU2019379325A1
(en)
|
2018-11-16 |
2021-06-03 |
Genexine, Inc. |
Method of treating a tumor with a combination of IL-7 protein and an immune checkpoint inhibitor
|
US20220018828A1
(en)
|
2018-11-28 |
2022-01-20 |
Inserm (Institut National De La Santé Et La Recherche Médicale |
Methods and kit for assaying lytic potential of immune effector cells
|
WO2020115262A1
(en)
|
2018-12-07 |
2020-06-11 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Use of cd26 and cd39 as new phenotypic markers for assessing maturation of foxp3+ t cells and uses thereof for diagnostic purposes
|
TW202039459A
(en)
|
2018-12-11 |
2020-11-01 |
美商施萬生物製藥研發 Ip有限責任公司 |
Alk5 inhibitors
|
US20220047556A1
(en)
|
2018-12-17 |
2022-02-17 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Use of sulconazole as a furin inhibitor
|
MX2021008525A
(en)
|
2019-01-15 |
2021-11-12 |
Univ Nantes |
Mutated interleukin-34 (il-34) polypeptides and uses thereof in therapy.
|
EP3914289A1
(en)
|
2019-01-23 |
2021-12-01 |
Massachusetts Institute of Technology |
Combination immunotherapy dosing regimen for immune checkpoint blockade
|
WO2020169472A2
(en)
|
2019-02-18 |
2020-08-27 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods of inducing phenotypic changes in macrophages
|
WO2020198676A1
(en)
|
2019-03-28 |
2020-10-01 |
Bristol-Myers Squibb Company |
Methods of treating tumor
|
EP3946625A1
(en)
|
2019-03-28 |
2022-02-09 |
Bristol-Myers Squibb Company |
Methods of treating tumor
|
JP2022527972A
(en)
|
2019-04-02 |
2022-06-07 |
アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル |
How to predict and prevent cancer in patients with premalignant lesions
|
EP3952850A1
(en)
|
2019-04-09 |
2022-02-16 |
Institut National de la Santé et de la Recherche Médicale (INSERM) |
Use of sk2 inhibitors in combination with immune checkpoint blockade therapy for the treatment of cancer
|
EP3956446A1
(en)
|
2019-04-17 |
2022-02-23 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and compositions for treatment of nlrp3 inflammasome mediated il-1beta dependent disorders
|
MA55805A
(en)
|
2019-05-03 |
2022-03-09 |
Flagship Pioneering Innovations V Inc |
METHODS OF MODULATING IMMUNE ACTIVITY
|
WO2020236253A1
(en)
|
2019-05-20 |
2020-11-26 |
Massachusetts Institute Of Technology |
Boronic ester prodrugs and uses thereof
|
EP3976832A1
(en)
|
2019-05-30 |
2022-04-06 |
Bristol-Myers Squibb Company |
Methods of identifying a subject suitable for an immuno-oncology (i-o) therapy
|
US20220233691A1
(en)
|
2019-05-30 |
2022-07-28 |
Bristol-Myers Squibb Company |
Cell localization signature and combination therapy
|
JP2022534967A
(en)
|
2019-05-30 |
2022-08-04 |
ブリストル-マイヤーズ スクイブ カンパニー |
Multiple tumor gene signatures and their uses
|
EP3983432A1
(en)
|
2019-06-12 |
2022-04-20 |
Askgene Pharma, Inc. |
Novel il-15 prodrugs and methods of use thereof
|
JP2022538974A
(en)
|
2019-06-26 |
2022-09-07 |
マサチューセッツ インスチテュート オブ テクノロジー |
Immunomodulatory fusion protein-metal hydroxide complexes and methods thereof
|
EP3994270A1
(en)
|
2019-07-02 |
2022-05-11 |
Fred Hutchinson Cancer Research Center |
Recombinant ad35 vectors and related gene therapy improvements
|
WO2021024020A1
(en)
|
2019-08-06 |
2021-02-11 |
Astellas Pharma Inc. |
Combination therapy involving antibodies against claudin 18.2 and immune checkpoint inhibitors for treatment of cancer
|
GB201912107D0
(en)
|
2019-08-22 |
2019-10-09 |
Amazentis Sa |
Combination
|
US20220348653A1
(en)
|
2019-09-22 |
2022-11-03 |
Bristol-Myers Squibb Company |
Quantitative Spatial Profiling for LAG-3 Antagonist Therapy
|
EP3800201A1
(en)
|
2019-10-01 |
2021-04-07 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Cd28h stimulation enhances nk cell killing activities
|
US20220363776A1
(en)
|
2019-10-04 |
2022-11-17 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and pharmaceutical composition for the treatment of ovarian cancer, breast cancer or pancreatic cancer
|
US11459389B2
(en)
|
2019-10-24 |
2022-10-04 |
Massachusetts Institute Of Technology |
Monoclonal antibodies that bind human CD161
|
WO2021092220A1
(en)
|
2019-11-06 |
2021-05-14 |
Bristol-Myers Squibb Company |
Methods of identifying a subject with a tumor suitable for a checkpoint inhibitor therapy
|
WO2021092221A1
(en)
|
2019-11-06 |
2021-05-14 |
Bristol-Myers Squibb Company |
Methods of identifying a subject with a tumor suitable for a checkpoint inhibitor therapy
|
CA3160479A1
(en)
|
2019-11-08 |
2021-05-14 |
Bristol-Myers Squibb Company |
Lag-3 antagonist therapy for melanoma
|
AU2020385400A1
(en)
|
2019-11-22 |
2022-06-09 |
Theravance Biopharma R&D Ip, Llc |
Substituted 1,5-naphthyridines or quinolines as ALK5 inhibitors
|
US20230114107A1
(en)
|
2019-12-17 |
2023-04-13 |
Flagship Pioneering Innovations V, Inc. |
Combination anti-cancer therapies with inducers of iron-dependent cellular disassembly
|
KR20220118481A
(en)
|
2019-12-19 |
2022-08-25 |
브리스톨-마이어스 스큅 컴퍼니 |
Combinations of DGK inhibitors and checkpoint antagonists
|
KR20220139915A
(en)
|
2020-02-06 |
2022-10-17 |
브리스톨-마이어스 스큅 컴퍼니 |
IL-10 and its uses
|
EP4126824A1
(en)
|
2020-03-31 |
2023-02-08 |
Theravance Biopharma R&D IP, LLC |
Substituted pyrimidines and methods of use
|
WO2021216572A1
(en)
|
2020-04-20 |
2021-10-28 |
Massachusetts Institute Of Technology |
Lipid compositions for delivery of sting agonist compounds and uses thereof
|
EP4139289A1
(en)
|
2020-04-21 |
2023-03-01 |
University of Rochester |
Inhibitors of human epididymus protein 4
|
JP2023524639A
(en)
|
2020-04-22 |
2023-06-13 |
アイオバンス バイオセラピューティクス,インコーポレイテッド |
Manufacturing adjustment system and adjustment method of cells for patient-specific immunotherapy
|
EP4162037A1
(en)
|
2020-06-03 |
2023-04-12 |
MV Biotherapeutics SA |
Combination of an atp-hydrolyzing enzyme and an immune checkpoint modulator and uses thereof
|
TW202214623A
(en)
|
2020-06-10 |
2022-04-16 |
美商施萬生物製藥研發 Ip有限責任公司 |
Crystalline alk5 inhibitors and uses thereof
|
CN116096906A
(en)
|
2020-06-29 |
2023-05-09 |
旗舰创业创新五公司 |
Virus engineered to promote saenox delivery and use thereof in treating cancer
|
WO2022003156A1
(en)
|
2020-07-02 |
2022-01-06 |
Oncurious Nv |
Ccr8 non-blocking binders
|
CN116249716A
(en)
|
2020-07-07 |
2023-06-09 |
康愈有限责任公司 |
MIC antibodies and binding agents and methods of use thereof
|
MX2023000197A
(en)
|
2020-07-07 |
2023-02-22 |
BioNTech SE |
Therapeutic rna for hpv-positive cancer.
|
US20230295146A1
(en)
|
2020-07-24 |
2023-09-21 |
The University Of Rochester |
Inhibitors of interleukin-1 receptor-associated kinases 1 and 4
|
BR112023003427A2
(en)
|
2020-08-28 |
2023-03-21 |
Bristol Myers Squibb Co |
LAG-3 ANTAGONIST THERAPY FOR HEPATOCELLULAR CARCINOMA
|
JP2023538955A
(en)
|
2020-08-31 |
2023-09-12 |
ブリストル-マイヤーズ スクイブ カンパニー |
Cellular localization signatures and immunotherapy
|
CA3196496A1
(en)
|
2020-10-23 |
2022-04-28 |
Laurence David TOMS |
Lag-3 antagonist therapy for lung cancer
|
WO2022120179A1
(en)
|
2020-12-03 |
2022-06-09 |
Bristol-Myers Squibb Company |
Multi-tumor gene signatures and uses thereof
|
WO2022130206A1
(en)
|
2020-12-16 |
2022-06-23 |
Pfizer Inc. |
TGFβr1 INHIBITOR COMBINATION THERAPIES
|
TW202245808A
(en)
|
2020-12-21 |
2022-12-01 |
德商拜恩迪克公司 |
Therapeutic rna for treating cancer
|
WO2022135667A1
(en)
|
2020-12-21 |
2022-06-30 |
BioNTech SE |
Therapeutic rna for treating cancer
|
WO2022135666A1
(en)
|
2020-12-21 |
2022-06-30 |
BioNTech SE |
Treatment schedule for cytokine proteins
|
WO2022136650A1
(en)
|
2020-12-24 |
2022-06-30 |
Oncurious Nv |
Murine cross-reactive human ccr8 binders
|
CA3206124A1
(en)
|
2020-12-24 |
2022-06-30 |
Vib Vzw |
Non-blocking human ccr8 binders
|
US20240076391A1
(en)
|
2020-12-24 |
2024-03-07 |
Oncurious Nv |
Human ccr8 binders
|
WO2022146948A1
(en)
|
2020-12-28 |
2022-07-07 |
Bristol-Myers Squibb Company |
Subcutaneous administration of pd1/pd-l1 antibodies
|
WO2022146947A1
(en)
|
2020-12-28 |
2022-07-07 |
Bristol-Myers Squibb Company |
Antibody compositions and methods of use thereof
|
CA3208974A1
(en)
*
|
2021-01-20 |
2022-07-28 |
Bioentre Llc |
Ctla4-binding proteins and methods of treating cancer
|
CN117222667A
(en)
*
|
2021-03-16 |
2023-12-12 |
Jn生物科学有限责任公司 |
Bifunctional molecules for the treatment of immune disorders
|
CA3214085A1
(en)
|
2021-03-31 |
2022-10-06 |
Darby Rye Schmidt |
Thanotransmission polypeptides and their use in treating cancer
|
EP4314068A1
(en)
|
2021-04-02 |
2024-02-07 |
The Regents Of The University Of California |
Antibodies against cleaved cdcp1 and uses thereof
|
TW202304524A
(en)
|
2021-04-10 |
2023-02-01 |
美商普方生物製藥美國公司 |
Folr1 binding agents, conjugates thereof and methods of using the same
|
WO2022226317A1
(en)
|
2021-04-23 |
2022-10-27 |
Profoundbio Us Co. |
Anti-cd70 antibodies, conjugates thereof and methods of using the same
|
WO2022229644A1
(en)
|
2021-04-28 |
2022-11-03 |
Mina Therapeutics Limited |
Combination therapies comprising c/ebp alpha sarna
|
WO2022251359A1
(en)
|
2021-05-26 |
2022-12-01 |
Theravance Biopharma R&D Ip, Llc |
Bicyclic inhibitors of alk5 and methods of use
|
AU2022288058A1
(en)
|
2021-06-07 |
2023-11-16 |
Agonox, Inc. |
Cxcr5, pd-1, and icos expressing tumor reactive cd4 t cells and their use
|
KR20240026507A
(en)
|
2021-06-29 |
2024-02-28 |
플래그쉽 파이어니어링 이노베이션스 브이, 인크. |
Immune cells engineered to promote thananotransmission and uses thereof
|
WO2023280790A1
(en)
|
2021-07-05 |
2023-01-12 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Gene signatures for predicting survival time in patients suffering from renal cell carcinoma
|
CA3225254A1
(en)
|
2021-07-13 |
2023-01-19 |
BioNTech SE |
Multispecific binding agents against cd40 and cd137 in combination therapy for cancer
|
TW202333802A
(en)
|
2021-10-11 |
2023-09-01 |
德商拜恩迪克公司 |
Therapeutic rna for lung cancer
|
WO2023077034A1
(en)
|
2021-10-28 |
2023-05-04 |
Lyell Immunopharma, Inc. |
Methods for culturing immune cells
|
IL309227A
(en)
|
2021-10-29 |
2024-02-01 |
Bristol Myers Squibb Co |
Lag-3 antagonist therapy for hematological cancer
|
WO2023092099A1
(en)
|
2021-11-19 |
2023-05-25 |
Ardeagen Corporation |
Gpc3 binding agents, conjugates thereof and methods of using the same
|
WO2023130081A1
(en)
|
2021-12-30 |
2023-07-06 |
Neoimmunetech, Inc. |
Method of treating a tumor with a combination of il-7 protein and vegf antagonist
|
WO2023147371A1
(en)
|
2022-01-26 |
2023-08-03 |
Bristol-Myers Squibb Company |
Combination therapy for hepatocellular carcinoma
|
WO2023161453A1
(en)
|
2022-02-24 |
2023-08-31 |
Amazentis Sa |
Uses of urolithins
|
WO2023164638A1
(en)
|
2022-02-25 |
2023-08-31 |
Bristol-Myers Squibb Company |
Combination therapy for colorectal carcinoma
|
WO2023168404A1
(en)
|
2022-03-04 |
2023-09-07 |
Bristol-Myers Squibb Company |
Methods of treating a tumor
|
WO2023170606A1
(en)
|
2022-03-08 |
2023-09-14 |
Alentis Therapeutics Ag |
Use of anti-claudin-1 antibodies to increase t cell availability
|
WO2023178329A1
(en)
|
2022-03-18 |
2023-09-21 |
Bristol-Myers Squibb Company |
Methods of isolating polypeptides
|
WO2023196987A1
(en)
|
2022-04-07 |
2023-10-12 |
Bristol-Myers Squibb Company |
Methods of treating tumor
|
WO2023235847A1
(en)
|
2022-06-02 |
2023-12-07 |
Bristol-Myers Squibb Company |
Antibody compositions and methods of use thereof
|
WO2023240287A1
(en)
|
2022-06-10 |
2023-12-14 |
Bioentre Llc |
Combinations of ctla4 binding proteins and methods of treating cancer
|
WO2024040175A1
(en)
|
2022-08-18 |
2024-02-22 |
Pulmatrix Operating Company, Inc. |
Methods for treating cancer using inhaled angiogenesis inhibitor
|
WO2024052356A1
(en)
|
2022-09-06 |
2024-03-14 |
Institut National de la Santé et de la Recherche Médicale |
Inhibitors of the ceramide metabolic pathway for overcoming immunotherapy resistance in cancer
|